Expanding educational infrastructure for American Society for Preventive Cardiology by Peter P. Toth

Get full text

Celebrating ASPC's achievements and introducing new educational offerings by Peter P. Toth

Get full text

ASPC president's page: Getting back to basics one patient at a time by Peter P. Toth

Get full text

President's page: ASPC is leading the way in preventive cardiology by Peter P. Toth

Get full text

The bandwidth of preventive cardiology continues to increase: Meeting the challenge head on by Peter P. Toth

Get full text

Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right by Peter P. Toth

Get full text

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease by Alberto J Lorenzatti, Peter P Toth

Get full text

Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines. by Peter P. Toth, MD, PhD

Get full text

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? by Maciej Banach, Stanisław Surma, Peter P. Toth

Get full text

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease by Mohanad Gabani, Michael D Shapiro, Peter P Toth

Get full text

Comparison of low-density lipoprotein cholesterol level calculated using the modified Martin/Hopkins estimation or the Friedewald formula with direct homogeneous assay measured low... by Istvan Reiber, Laszlo Mark, Gyorgy Paragh, Peter P. Toth

Get full text

There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations fo... by Michael E. Makover, Michael D. Shapiro, Peter P. Toth

Get full text

Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review by Peter P. Toth, Prediman K. Shah, Norman E. Lepor

Get full text

Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention by Peter P. Toth, Peter P. Toth, Jean Ferrières, Max Waters, Martin Bødtker Mortensen, Nick S. R. Lan, Nick S. R. Lan, Nathan D. Wong

Get full text

Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis by Peter P. Toth, Craig Granowitz, Michael Hull, Amy Anderson, Sephy Philip

Get full text

Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review by Arrigo F. G. Cicero, Federica Fogacci, Anca Pantea Stoian, Peter P. Toth

Get full text

Differentiating EPA from EPA/DHA in cardiovascular risk reduction by Peter P. Toth, M. John Chapman, Klaus G. Parhofer, John R. Nelson

Get full text

Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007–2014 by Wenjun Fan, Sephy Philip, Peter P. Toth, Craig Granowitz, Wong Nathan D.

Get full text

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With... by Peter P. Toth, Craig Granowitz, Michael Hull, Djibril Liassou, Amy Anderson, Sephy Philip

Get full text

Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies by Arrigo F.G. Cicero, Federica Fogacci, Alberto Zambon, Peter P. Toth, Claudio Borghi

Get full text